

FUNDING AND DISCLOSURE

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:

Dr. Roger McIntyre has received research grant support from CIHR/ GACD/ Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra-Cellular, and Abbvie. Dr. Roger McIntyre is a shareholder and CEO of Champignon Brands, which acquired the Canadian Rapid Treatment Center of Excellence in May 2020.

JDR has received research grant support from the Canadian Cancer Society, Canadian Psychiatric Association, American Psychiatric Association, American Society of Psychopharmacology, University of Toronto, University Health Network Centre for Mental Health, Joseph M. West Family Memorial Fund and Timeposters Fellowship and industry funding for speaker/consultation/research fees from Janssen, Allergan, Lundbeck, Sunovion and COMPASS. JDR is the medical director of a private clinic providing intravenous ketamine infusions and intranasal esketamine for depression.

KK is the Vice President of Operations at the Canadian Rapid Treatment Center of Excellence (CRTCE). KK is a shareholder of Champignon Brands, which acquired the CRTCE in May 2020.

All other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.